We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Surgical Innovations Group Plc | SUN | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 0.50 | 08:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 0.50 | 0.50 | 0.50 | 0.50 |
| Industry Sector |
|---|
| HEALTH CARE EQUIPMENT & SERVICES |
| Top Posts |
|---|
Posted at 13/4/2024 17:44 by barrenwuffet2 Let us imagine for a moment you are correct and CMR perform 36,000 cases in the coming year. How much do CMR charge for a set of SUN products? Say £50? So SUN would sell them to CMR at around £25.00 - maybe more, maybe less but this order of magnitude.36,000 x £24 is £900,000. Is under £1m growth from what you say is a key driver going to change the world for SUN? |
Posted at 11/4/2024 04:03 by buywell3 CMR Surgical sales will IMO now start to help Surgical Innovations begin its recoveryRemember, March 23rd 2022 CMR Surgical & Surgical Innovations develop new surgical hybrid port access system ~ Surgical Innovations’ new YelloPort Elite™ 5mm, with reusable trocar and canula, reduces cost and waste generated when compared with traditional fully single use Port Access Systems ~ Developed with CMR Surgical, the port access system is the latest addition to Surgical Innovation’s Resposable® range of products and is designed specifically for the Versius® Surgical Robotic System CMR Surgical announced Versius robots have performed 1,000 operations Nov 25th 2020 2 and one half years later CMR Surgical announced Versius robots have performed 10,000 operations Apr 20th 2023 11 months later CMR Surgical announced Versius robots have performed 20,000 operations Mar 21st 2024 On january 4th 2024 CMR Surgical announced that 17,000 operations had been performed with some interesting stats ~ After a record quarter, CMR closes the year with a Versius global install base more than 50% higher than 2022 ~ Over 17,000 surgical procedures completed using Versius, representing a procedural growth rate of over 60% in 2023, compared with 2022, with an increasing number of complex surgeries being undertaken with Versius ~ Continued expansion into new markets in Europe, Asia, Middle East, Africa, and Latin America ----- It is worth also remembering that for the majority of Versius robotic operations , 4 robotic arms are normally used meaning 4 new YelloPort Elite™ 5mm devices being used with one of those also used for viewing purposes with an optical disposable trocar ---- which at long last Surgical Innovations are now providing There is every chance in the next 12 months Versius can hit at least 36,000 operations performed or in other words carry out 16,000 operations from Mar 21st 2024 to Mar 21st 2025 New seals are needed as supplied by surgical Innovations for every operation/Versius arm that uses a new YelloPort Elite™ 5mm trocar So not only are SUN providing the new YelloPort Elite™ 5mm optical trocars to CMR Surgical , they also keep selling 3 sets of seals and a plastic optical trocar for many of these operations It would be nice to think that SUN are in and have been for some time , in the process of designing another instrument that CMR Surgical will also use dyor |
Posted at 19/3/2024 21:45 by z1co cashfloJust ignore PUGUGLY ,the idiot thinks he's clever.That's the 2nd of my stocks he's deramped in the last 4 weeks , he first tried to deramp PIP and now SUN. Z1CO is on his case , no one likes to have a monkey on their back. |
Posted at 04/3/2024 17:45 by z1co Hi cashfloHolding some shares is very boring , it looks like SUN falls in this category. I'm very optimistic that when they announce results this month the outlook for 2024 will be much better than last year and this will put some life back in to these dead shares. |
Posted at 29/1/2024 08:15 by z1co Year-end 2023 Trading UpdateRecord sales and operational efficiency programme on track Surgical Innovations Group Plc (AIM: SUN), the designer, manufacturer and distributor of innovative technology for minimally invasive surgery, provides an update on trading for the year ended 31 December 2023, with sales marginally head of market expectations. Unaudited Financials Revenues for the year are expected to be approximately £12.0m, an increase of 6% compared with the prior year (2022: £11.3m). Group revenues continued to grow in H2 in line with the Board's expectations, with key markets and OEM sales in particular performing strongly. Sales for the second half of the year were approximately 13% higher than the first half. The Group expects to report a positive adjusted EBITDA1 of £0.2m, in-line with expectations. Operational improvements continue to be implemented in the new financial year and are expected to enhance future profitability. The closing net cash2 balances of the Group stood at approximately £0.36m at 31 December 2023 (30 June 2023: £0.38m), with available gross cash resources at 31 December 2023 of £2.21m (30 June 2023: £2.41m) including an undrawn invoice discounting facility of £1.0m (30 June 2023: £1.0m). UK sales remained strong in H2 2023, driven by the resonance of the sustainability messaging for both the NHS and Private Healthcare providers. Growing global acceptance of the need to adopt more sustainable solutions in healthcare is also driving growth in key markets in Europe, APAC and ROW. Despite supply chain challenges in H2 2023, the OEM business produced strong sales and carried a positive order book into 2024. The recently implemented operating efficiency programme, which includes the re-introduction of a 5-day working week, is on track to deliver further improvements to the gross margin in 2024. Current trading and outlook While continued industrial action in the NHS has impacted the volume of elective surgeries and slowed some of the progress with evaluations, it is not anticipated to affect Q1 sales. Across the Company's distribution network, expected sales remain on track to deliver management forecasts. Some of the supply chain issues seen last year have impacted OEM sales, but these are now resolved and are not expected to have a material bearing on Q1 performance. David Marsh, CEO of Surgical Innovations Group Plc, said: "Despite a challenging 2023, the Company finished the year with record sales and entered 2024 with an encouraging order book. The recent actions taken to improve operational efficiencies, together with continued increasing sales momentum, give the Board confidence that we have put the business onto a sustainable growth trajectory for 2024 and beyond." |
Posted at 29/1/2024 08:14 by z1co !FOLLOWFEEDYear-end 2023 Trading Update: Record sales and operational efficiency programme on track Surgical Innovations Group Plc (AIM: SUN), the designer, manufacturer and distributor of innovative technology for minimally invasive surgery, provides an update on trading for the year ended 31 December 2023, with sales marginally head of market expectations. |
Posted at 25/9/2023 12:06 by barrenwuffet2 I’m not sure SUN investors are getting behind the AMS and CMR newsfeed. |
Posted at 11/6/2023 09:23 by buywell3 Yet more good newsThere is growth ahead within the Global Laparoscopic Devices Market Surgical Innovations have an agreement with Microline Surgical , whereby each company markets some of the others products in their own home country--- Microline Surgical get mentioned here: The Global Laparoscopic Devices Market Size was valued at USD 7.2 billion in 2022 and the worldwide Laparoscopic Devices Market size is expected to reach USD 16.3 billion by 2032, according to a research report published by Spherical Insights & Consulting. Companies Covered: Karl Storz SE & CO. Kg, Medtronic, Johnson and Johnson, Olympus Corporation, CONMED Corporation, B. Braun Melsungen AG, The Cooper Companies Inc., Richard Wolf GmbH, Microline Surgical, BD, Welfare Medical Ltd, Intuitive Surgical, Shenzen Mindray Bio Medical Electronics Co., Ltd and among others. Surgical Innovations have a 5year deal in place with Microline Surgical RNS Number : 0224P Surgical Innovations Group PLC 15 February 2021 5-year USA distribution agreement Distribution agreement signed with Microline Surgical Inc for YelloPort+PlusTM and YelloPort EliteTM Surgical Innovations Group plc (AIM: SUN), the designer, manufacturer and distributor of innovative medical technology for minimally invasive surgery ("MIS"), announces a new USA distribution agreement with Microline Surgical Inc. ("Microline") for the Company's range of YelloPort+PlusTM and YelloPort EliteTM Access Devices. The 5-year agreement brings a significant opportunity to SI for growth in the US Trocar market. Microline's sales & marketing structure is ideally placed to leverage their experience with Resposable surgical instruments to effectively drive US sales of YelloPort+PlusTM and YelloPort EliteTM Access Devices. Based near Boston, MA, U.S.A. Microline designs, manufactures and distributes high quality instruments aimed at the MIS market. Its portfolio of products is complementary to those offered by SI with a focus on the resposable ethos of cost and sustainability. SI has a long established relationship with Microline, where it has an exclusive GB distribution agreement for Microline instruments that are complementary to the SI branded range. Timothy Gehlmann, President & CEO of Microline, noted: "Microline is excited to add the YelloPort line of trocars from SI to our product portfolio. The SI trocar line complements our MIS instrument line by broadening our solution offering to customers." Adam Power, Group Development Director at SI, added: "The United States accounts for almost half of the worldwide trocar market. Microline has a direct sales team with considerable experience in the selling of Resposable surgical devices. Microline and Surgical Innovations, through its UK subsidiary Elemental Healthcare, share a long history of synergy and growth and we are very excited to replicate this successful relationship in the United States." dyor |
Posted at 25/5/2023 07:31 by buywell3 No trades buywell can see over the last few days published reflect this ??Todays RNS Surgical Innovations Group plc (AIM: SUN), the designer, manufacturer and distributor of innovative medical technology for minimally invasive surgery ("MIS"), was notified on 24 May 2023 that, on 24 May 2023, Janis Glenn (wife of Jonathan Glenn, Non-executive Director) purchased 1,315,482 ordinary shares of 1p each in Surgical Innovations ("Ordinary Shares") at a price of 2.28 pence per share. Surgical Innovations Group PLC 22 May 2023 Surgical Innovations Group Plc Directorate changes and board succession planning Surgical Innovations Group Plc (AIM: SUN), the designer, manufacturer and distributor of innovative technology for minimally invasive surgery, announces the appointment of Jonathan Glenn as Senior Independent Non-executive Director and Chairman-designate of the Company with immediate effect. Jonathan is an experienced board director and chairman, with an excellent track record in the medical device sector. He is currently Non-executive Chairman of Tissue Regenix plc, and was formerly Group CEO of Consort Medical Plc from 2007 to 2020, where he oversaw the £230m acquisition of a European contract development and manufacturing organisation. Jonathan led the business as CEO until its acquisition for £505m in 2020. Jonathan is a member of the Institute of Chartered Accountants in England and Wales. He joins the board in anticipation of the upcoming retirement of Professor Mike McMahon, the founder of the Company, who retires from the board at the Annual General Meeting of the Company expected to take place on 27 June 2023. Following an orderly handover process, Jonathan will succeed Nigel Rogers as Chairman upon announcement of the interim results expected in September 2023. Nigel has indicated his intention to remain on the board until an additional independent non-executive director has been appointed. Chairman of the Company, Nigel Rogers, commented: "It has been my great pleasure to lead the board since my appointment in 2015, and especially to work alongside Prof. Mike McMahon. As part of our planned succession arrangements, we are now delighted to have Jonathan joining us, and look forward to working with him to complete the transition in board composition for the next stage in the Company's evolution." Past Trades May 23, 2023 1.95p 1.81p 1.81p 1.95p 756 May 22, 2023 1.95p 2.05p 2.05p 1.95p 100,000 May 18, 2023 1.95p 1.86p 1.86p 1.95p 382 May 17, 2023 1.95p 2.05p 1.86p 1.95p 49,683 May 16, 2023 1.95p 2.05p 1.86p 1.95p 116,476 May 15, 2023 1.95p 1.86p 1.86p 1.95p 34,500 May 12, 2023 1.95p 2.07p 1.86p 1.95p 210,867 May 11, 2023 1.95p 1.86p 1.86p 1.95p 3,000 May 10, 2023 1.95p 2.07p 1.80p 1.95p 398,351 May 9, 2023 1.95p 2.07p 1.85p 1.95p 17,380 May 5, 2023 1.95p 2.05p 2.05p 1.95p 376,594 May 4, 2023 1.95p 2.05p 2.05p 1.95p 1,267 May 2, 2023 1.95p 2.05p 2.05p 1.95p 4,878 Apr 27, 2023 1.95p 2.05p 1.84p 1.95p 157,461 Apr 26, 2023 1.95p 2.05p 1.84p 1.95p 270,249 Apr 25, 2023 1.95p 1.84p 1.84p 1.95p 51,178 Apr 24, 2023 1.95p 1.84p 1.84p 1.95p 20,000 Apr 21, 2023 1.95p 1.96p 1.82p 1.95p 572,078 Apr 20, 2023 1.95p 1.96p 1.81p 1.95p 191,274 Apr 19, 2023 1.95p 1.96p 1.83p 1.95p 256,282 Apr 18, 2023 1.95p 1.96p 1.87p 1.95p 11,490 Apr 17, 2023 1.95p 1.87p 1.87p 1.95p 125,000 Apr 14, 2023 1.95p 1.97p 1.85p 1.95p 550,000 Apr 12, 2023 1.95p 1.97p 1.97p 1.95p 100,508 Apr 11, 2023 1.95p 1.97p 1.83p 1.95p 82,107 Apr 6, 2023 1.95p 1.97p 1.97p 1.95p 101,221 Apr 4, 2023 1.95p 1.98p 1.98p 1.95p 407 Apr 3, 2023 1.95p 1.98p 1.83p 1.95p 177,465 Mar 31, 2023 1.95p 2.10p 1.80p 1.95p 12,240 Mar 30, 2023 2.10p 2.09p 1.81p 1.95p 1,747,493 Mar 29, 2023 1.95p 2.03p 1.99p 2.05p 549,353 Mar 28, 2023 1.90p 1.99p 1.83p 1.90p 265,245 Mar 27, 2023 1.90p 1.99p 1.83p 1.90p 141,710 Mar 24, 2023 1.90p 1.83p 1.83p 1.90p 73,049 Mar 23, 2023 1.90p 1.99p 1.99p 1.90p 13,467 Mar 22, 2023 1.90p 1.99p 1.83p 1.90p 54,495 Mar 21, 2023 1.90p 1.83p 1.83p 1.90p 83,671 Mar 20, 2023 1.95p 1.99p 1.82p 1.90p 242,833 Mar 17, 2023 1.95p 1.99p 1.90p 1.95p 84,116 Mar 16, 2023 1.95p 1.99p 1.90p 1.95p 51,424 Mar 15, 2023 2.05p 2.05p 1.90p 1.95p 140,000 Mar 14, 2023 2.05p 2.08p 1.91p 2.05p 8,957 Mar 13, 2023 2.05p 2.08p 1.90p 2.05p 36,220 Mar 10, 2023 2.05p 1.92p 1.92p 2.05p 70,000 Mar 9, 2023 2.05p 1.92p 1.92p 2.05p 18,897 Mar 8, 2023 2.05p 2.15p 1.92p 2.05p 6,975 Mar 7, 2023 2.05p 2.15p 1.90p 2.05p 53,746 Mar 6, 2023 2.15p 2.21p 2.00p 2.05p 123,158 Mar 3, 2023 2.15p 2.27p 2.00p 2.15p 679,024 Mar 2, 2023 2.05p 2.29p 2.00p 2.15p 534,776 |
Posted at 30/3/2023 22:33 by buywell3 This is a must listen to video presentation of the Final results IMOIt is buywells understanding that Singer Capital have a EBITDA forecast for SUN at 0.9 Million pounds for 2023 buywell opines that due to the pent up demand in the US and Japan for 5mm Elite trocars and optical trocars --- plus new orders from India/Germany/other countries due to new market penetration by way of gaining entry to new hospital sales of SI devices on the back of CMR Surgical sales which of course include the 5mm Elite trocar and the optical trocar plus consumables = Add on sales of other existing SI instrumentation and EH offerings plus consumables for both ongoing Due to this buywell is forecasting more than 1M profit for 2023 Double that for 2024 as EU, US and APAC market penetration increases with MDR completed and the new Logi range of graspers and cutters gets added = 2024 profit 2.5 Million pounds Then we have the AMS expected sales of LiquibandFix8 in the USA --- starting soon This alone could be transformational if PMA is given by the US later this financial year Assuming a profit of 1M the P/E for SUN would be 19.12 at todays Mkt Cap At a 2024 2.5M profit the SUN forward P/E would be 7.6 dyor |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
